Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 7,631 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumor, Hepatocellular Carcinoma
Interventions
TORL-4-500
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 5 more
Conditions
Solid Tumor
Interventions
Topotecan, Sorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
3 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Hartford, Connecticut • Wilmington, Delaware + 6 more
Conditions
Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
Interventions
3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine, Chemotherapy, Computed Tomography, Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Quality-of-Life Assessment, X-Ray Imaging
Radiation · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
678
States / cities
Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Regional Anesthesia Block in Fibula Free Flap Reconstruction

NCT03906838
Conditions
Anesthesia, Local, Surgery, Opioid Use, Pain, Postoperative, Head and Neck Neoplasms
Interventions
Ropivacaine injection
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
Interventions
Evolocumab, Placebo
Drug · Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more
Conditions
Alzheimer Disease
Interventions
Simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
51 Years to 89 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
107
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 94 more
Conditions
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Interventions
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
791
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 512 more
Completed Phase 3 Interventional Results available

Long Term Safety of Naldemedine

NCT01965652
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more
Conditions
Colorectal Cancer
Interventions
bevacizumab, capecitabine, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
Prologue Research International
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
52
States / cities
Birmingham, Alabama • Tucson, Arizona • Greenbrae, California + 47 more
Conditions
Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Bladder Cancer, Uterine Cancer, Kidney Cancer, Renal Pelvis Cancer, Pancreatic Cancer, Liver Cancer, Stomach Cancer, Ovarian Cancer, Esophageal Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
5,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
119
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 106 more
Conditions
Insomnia Disorder
Interventions
Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 47 more
Completed No phase listed Observational

Novel Cardiac Signal Processing System

NCT04112433
Conditions
Cardiac Arrhythmia
Interventions
PURE EP 2
Device
Lead sponsor
BioSig Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Jacksonville, Florida • Boston, Massachusetts • Austin, Texas
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Placebo
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
122
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 119 more
Completed Phase 2 Interventional Results available

Efficacy of Methotrexate in Myasthenia Gravis

NCT00814138
Conditions
Myasthenia Gravis
Interventions
Methotrexate, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
15
States / cities
Phoenix, Arizona • Fresno, California • Irvine, California + 12 more
Conditions
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen
Drug · Biological
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
185
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more
Conditions
Sarcoma
Interventions
dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Conditions
Major Depressive Disorder
Interventions
PRAX-114, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 65 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
30
States / cities
Phoenix, Arizona • Garden Grove, California • Lafayette, California + 27 more
Completed Not applicable Interventional Results available

Proton Therapy for Low and Intermediate Risk Prostate Cancer

NCT00693238
Conditions
Prostate Cancer
Interventions
Low Risk Proton Radiation, Intermediate Risk Proton Radiation
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions
Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
1,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
181
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more
Conditions
Arrhythmias, Cardiac
Interventions
Arrhythmia Mapping
Device
Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 2 more
Conditions
Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Interventions
Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
6,385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
181
States / cities
Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 140 more
Conditions
Multiple Myeloma
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more
Conditions
Dermatitis, Atopic
Interventions
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
3,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
156
States / cities
Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
Conditions
Degenerative Disc Disease, Degenerative Scoliosis
Interventions
Spinal Fusion, Spinal Deformities Correction
Device
Lead sponsor
VB Spine, LLC
Industry
Eligibility
18 Years and older
Enrollment
5,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
7
States / cities
Jacksonville, Florida • Scarborough, Maine • Southfield, Michigan + 4 more